The size of the Over the counter (OTC) drugs market in Asia-Pacific region has been estimated at USD 51.57 Million in 2019 and is projected to reach USD 83.09 Million by 2024 at a CAGR of 10.01% during the forecast period from 2019 to 2024.
Over the counter (OTC) drugs are the safe and effective drugs, which can be bought without doctor’s prescription, which are used for common ailments. Acetaminophen, aspirin and ibuprofen are the most common OTC drugs.
This has become a big hit in Asia, due to easy accessibility, low cost, convenience and customer-empowering qualities. The increasing number of chemists and pharma dispensaries is making the drugs readily available, thus, making it feasible for the consumers.
With the pro-active approach shown by public in Asia-Pacific region, the OTC drugs are made lower-priced. This is a major point which is driving the market. The alarming issues of drug substance abuse and lack of awareness in under-developed areas are constraining the progress of the market.
This research report segmented and sub-segmented into the following categories:
Japanese market is forecasted to saturate soon due to economic stagnation. Increasing adoption of western lifestyles and growing prosperities is leading to increase in market size and OTC demand.
The Top companies leading in the APAC Over The Counter (OTC) Drugs Market profiled in the report are GlaxoSmithKline, Johnson and Johnson, Novartis, Bayer, Pfizer, Sanofi and Takeda are the leading companies that contribute to Asia-Pacific market.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Analgesics
5.1.2 Cough, Cold and Flu Products
5.1.3 Vitamins and Minerals
5.1.4 Dermatological Products
5.1.5 Gastrointestinal Products
5.1.6 Ophthalmic Products
5.1.7 Sleep Aid Products
5.1.8 Weight Loss/Diet Products
5.1.9 Others
5.2 By Formulation Type
5.2.1 Tablets
5.2.2 Liquids
5.2.3 Ointments
5.2.4 Sprays
5.3 Distribution Channels
5.3.1 Pharmacies
5.3.2 Supermarkets/Hypermarkets
5.3.3 Convenience stores
5.3.4 Others (Online Drug Stores)
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 GlaxoSmithKline
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Johnson and Johnson
8.3 Novartis
8.4 Bayer
8.5 Pfizer
8.6 Boehringer Ingelheim
8.7 Sanofi
8.8 Takeda
8.9 PGT Healthcare
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
